Skip to main content
Premium Trial:

Request an Annual Quote

Spotfire, Iconix Partner in Tool Development

SAN FRANCISCO, Aug. 5 - Spotfire and Iconix Pharmaceuticals have partnered in a three-year collaboration to develop chemogenomics and toxicogenomics data analysis tools, the companies said today.

 

The collaboration will integrate Spotfire's visualization software with Iconix's content and data mining tools, said an Iconix spokesperson.

 

Spotfire's DecisionSite for Functional Genomics tools will be integrated with Iconix's DrugMatrix drug profiling and prediction system, which is being developed with MDS Pharma Services and offered by subscription by Incyte Genomics.

 

Financial details of the agreement were not disclosed.

 

Click here for more information.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.